YD Bio Limited Warrants
YDESW
NASDAQ Global Select0.28
USD
+0.02
- -
YD Bio Limited Warrants
YDESW
(NASDAQ Global Select)
Recent
price
0.28
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- YD Bio Limited (Nasdaq: YDES; YDESW), a biotechnology company founded in 2013 and headquartered in Taipei, Taiwan, focuses on blood-based cancer detection through non-invasive DNA methylation analysis for early detection, treatment monitoring, and recurrence tracking of cancers including pancreatic and breast; develops stem cell- and exosome-based therapeutics such as limbal stem cell-derived exosomes for regenerative medicine targeting ocular surface conditions, dry eye disease, glaucoma, and corneal repair; supplies high-quality clinical trial drugs and nutritional supplements to pharmaceutical companies including Novartis; and offers innovative ophthalmic products comprising contact lenses and artificial tears for dry eye care. The company serves healthcare providers, hospitals, insurance companies, pharmacies, and optometrists across the United States, Europe, Asia-Pacific, and Taiwan through research collaborations, licensing agreements, and distribution channels. In August 2025, YD Bio completed a business combination with Breeze Holdings Acquisition Corp and a concurrent PIPE financing yielding $13.2 million in gross proceeds to fund operations and innovation; listed its ordinary shares and warrants on Nasdaq Global Market under YDES and YDESW; signed an exclusive license on September 30, 2025, for breast cancer detection technology across the U.S., Europe, and Asia-Pacific; obtained licenses from EG BioMed Taiwan for pancreatic cancer detection and established a U.S. laboratory; secured patent and technology authorizations from 3D Global Biotech for corneal mesenchymal stem cell and exosome applications in eye diseases; and announced U.S. ophthalmology market entry in November 2025 while advancing LSC exosome therapeutics.